The FDA has approved telisotuzumab vedotin-tllv for certain patients with non-small cell lung cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis) for the treatment of adult...
The FDA has approved belzutifan for certain patients with pheochromocytoma and paraganglioma. The U.S. Food and Drug Administration (FDA) has approved belzutifan (Welireg) for the treatment of patients 12 years and older with locally...
During the Presidential Select Symposium at the AACR Annual Meeting 2025, Patricia M. LoRusso, DO, PhD(h), FAACR, led a panel addressing the global cancer burden.
A single dose of HPV vaccine is highly effective, and not all cancers are increasing in people under 50.
For April 2025, the editors of AACR's 10 journals highlighted studies on evolution in glioblastoma, new cancer treatment approaches, and more.
The FDA has approved avutometinib and defactinib for certain patients with KRAS-mutated low-grade serous ovarian cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to avutometinib and defactinib (Avmapki Fakzynja Co-pack)...
Immunotherapy may treat some early-stage cancer patients without the need for surgery, and exercise found to counter many side effects of cancer treatment.
Adding pembrolizumab before and after surgery to standard of care improved outcomes in patients with previously untreated head and neck cancer.
People with metabolic syndrome may have elevated risk for breast cancer mortality, and immunotherapy keeps lung cancer at bay even after discontinuing treatment.
The FDA has approved penpulimab-kcqx for certain patients with nasopharyngeal carcinoma. The U.S. Food and Drug Administration (FDA) has approved penpulimab-kcqx in combination with chemotherapy for the first-line treatment of patients with nonkeratinizing nasopharyngeal carcinoma...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More